Author
Tuija Vasankari
Other affiliations: University of Turku
Bio: Tuija Vasankari is an academic researcher from Turku University Hospital. The author has contributed to research in topics: Atrial fibrillation & Cardioversion. The author has an hindex of 18, co-authored 58 publications receiving 2246 citations. Previous affiliations of Tuija Vasankari include University of Turku.
Topics: Atrial fibrillation, Cardioversion, Medicine, Cardioversions, Stroke
Papers
More filters
••
University of Zurich1, Hannover Medical School2, University of California, Davis3, Heidelberg University4, Ludwig Maximilian University of Munich5, Charité6, University of Kentucky7, University of Cologne8, Saarland University9, University of Duisburg-Essen10, University of Göttingen11, University of Hamburg12, University of Ulm13, Technische Universität München14, Otto-von-Guericke University Magdeburg15, John Radcliffe Hospital16, Winterthur Museum, Garden and Library17, University of Turku18, Gdańsk Medical University19, University of Warmia and Mazury in Olsztyn20, Medical University of Warsaw21, University of Cambridge22, University of Basel23, Catholic University of the Sacred Heart24, Innsbruck Medical University25, University of Greifswald26, Leiden University27, University of Glasgow28
TL;DR: Patients with takotsubo cardiomyopathy had a higher prevalence of neurologic or psychiatric disorders than did those with an acute coronary syndrome and physical triggers, acute neurologics or psychiatric diseases, high troponin levels, and a low ejection fraction on admission were independent predictors for in-hospital complications.
Abstract: BackgroundThe natural history, management, and outcome of takotsubo (stress) cardiomyopathy are incompletely understood. MethodsThe International Takotsubo Registry, a consortium of 26 centers in Europe and the United States, was established to investigate clinical features, prognostic predictors, and outcome of takotsubo cardiomyopathy. Patients were compared with age- and sex-matched patients who had an acute coronary syndrome. ResultsOf 1750 patients with takotsubo cardiomyopathy, 89.8% were women (mean age, 66.8 years). Emotional triggers were not as common as physical triggers (27.7% vs. 36.0%), and 28.5% of patients had no evident trigger. Among patients with takotsubo cardiomyopathy, as compared with an acute coronary syndrome, rates of neurologic or psychiatric disorders were higher (55.8% vs. 25.7%) and the mean left ventricular ejection fraction was markedly lower (40.7±11.2% vs. 51.5±12.3%) (P<0.001 for both comparisons). Rates of severe in-hospital complications including shock and death were ...
1,721 citations
••
University of Zurich1, University of California, San Diego2, University of Bremen3, University of Turin4, University Hospital Heidelberg5, University of Southern California6, Hannover Medical School7, Gdańsk Medical University8, Martin Luther University of Halle-Wittenberg9, Technische Universität München10, Leipzig University11, Charité12, HealthPartners13, University of Cologne14, University of Göttingen15, University of Kiel16, University of Ulm17, Otto-von-Guericke University Magdeburg18, John Radcliffe Hospital19, Winterthur Museum, Garden and Library20, Turku University Hospital21, Medical University of Warsaw22, University Hospital of Basel23, Catholic University of the Sacred Heart24, Greifswald University Hospital25, Heidelberg University26, University of Adelaide27, Charles University in Prague28, University of Florida29, Leiden University30, Mayo Clinic31, Imperial College London32
TL;DR: It is demonstrated that TTS can either be benign or a life-threating condition depending on the inciting stress factor, and a new classification based on triggers is proposed, which can serve as a clinical tool to predict short- and long-term outcomes of TTS.
192 citations
••
TL;DR: A smartphone-only solution for the detection of atrial fibrillation (AFib), which utilizes the built-in accelerometer and gyroscope sensors [inertial measurement unit, (IMU)] in the detection.
Abstract: We present a smartphone-only solution for the detection of atrial fibrillation (AFib), which utilizes the built-in accelerometer and gyroscope sensors [inertial measurement unit, (IMU)] in the detection. Depending on the patient's situation, it is possible to use the developed smartphone application either regularly or occasionally for making a measurement of the subject. The smartphone is placed on the chest of the patient who is adviced to lay down and perform a noninvasive recording, while no external sensors are needed. After that, the application determines whether the patient suffers from AFib or not. The presented method has high potential to detect paroxysmal (“silent”) AFib from large masses. In this paper, we present the preprocessing, feature extraction, feature analysis, and classification results of the envisioned AFib detection system based on clinical data acquired with a standard mobile phone equipped with Google Android OS. Test data was gathered from 16 AFib patients (validated against ECG), as well as a control group of 23 healthy individuals with no diagnosed heart diseases. We obtained an accuracy of 97.4% in AFib versus healthy classification (a sensitivity of 93.8% and a specificity of 100%). Due to the wide availability of smart devices/sensors with embedded IMU, the proposed methods could potentially also scale to other domains such as embedded body-sensor networks.
110 citations
••
14 May 2019
TL;DR: The results indicate that the flexible and wearable wristband based on microelectromechanical sensor (MEMS) elements array could be useful in remote monitoring of cardiovascular diseases and personalized medicine.
Abstract: There is an unmet clinical need for a low cost and easy to use wearable devices for continuous cardiovascular health monitoring. A flexible and wearable wristband, based on microelectromechanical sensor (MEMS) elements array was developed to support this need. The performance of the device in cardiovascular monitoring was investigated by (i) comparing the arterial pressure waveform recordings to the gold standard, invasive catheter recording (n = 18), (ii) analyzing the ability to detect irregularities of the rhythm (n = 7), and (iii) measuring the heartrate monitoring accuracy (n = 31). Arterial waveforms carry important physiological information and the comparison study revealed that the recordings made with the wearable device and with the gold standard device resulted in almost identical (r = 0.9–0.99) pulse waveforms. The device can measure the heart rhythm and possible irregularities in it. A clustering analysis demonstrates a perfect classification accuracy between atrial fibrillation (AF) and sinus rhythm. The heartrate monitoring study showed near perfect beat-to-beat accuracy (sensitivity = 99.1%, precision = 100%) on healthy subjects. In contrast, beat-to-beat detection from coronary artery disease patients was challenging, but the averaged heartrate was extracted successfully (95% CI: −1.2 to 1.1 bpm). In conclusion, the results indicate that the device could be useful in remote monitoring of cardiovascular diseases and personalized medicine.
86 citations
••
TL;DR: In patients undergoing transfemoral TAVI, the MANTA VCD showed a similar risk of VARC-2 vascular and bleeding complications compared to the ProGlide VCD, but it reduced significantly the need of additional VCDs for completion of hemostasis.
72 citations
Cited by
More filters
•
9,185 citations
••
TL;DR: The Task Force for the management of atrial fibrillation of the European Society of Cardiology has been endorsed by the European Stroke Organisation (ESO).
Abstract: The Task Force for the management of atrial fibrillation of the European Society of Cardiology (ESC)
Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC
Endorsed by the European Stroke Organisation (ESO)
5,255 citations
••
4,960 citations
••
Leipzig University1, University of Belgrade2, Leiden University3, Uppsala University4, University of Modena and Reggio Emilia5, University of Barcelona6, Carol Davila University of Medicine and Pharmacy7, National and Kapodistrian University of Athens8, François Rabelais University9, University of Melbourne10, Royal Melbourne Hospital11, University of Lisbon12, University of Birmingham13, University Medical Center Groningen14, University of Groningen15, University of Central Lancashire16
TL;DR: The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only and no commercial use is authorized.
Abstract: Supplementary Table 9, column 'Edoxaban', row 'eGFR category', '95 mL/min' (page 15). The cell should be coloured green instead of yellow. It should also read "60 mg"instead of "60 mg (use with caution in 'supranormal' renal function)."In the above-indicated cell, a footnote has also been added to state: "Edoxaban should be used in patients with high creatinine clearance only after a careful evaluation of the individual thromboembolic and bleeding risk."Supplementary Table 9, column 'Edoxaban', row 'Dose reduction in selected patients' (page 16). The cell should read "Edoxaban 60 mg reduced to 30 mg once daily if any of the following: creatinine clearance 15-50 mL/min, body weight <60 kg, concomitant use of dronedarone, erythromycin, ciclosporine or ketokonazole"instead of "Edoxaban 60 mg reduced to 30 mg once daily, and edoxaban 30 mg reduced to 15mg once daily, if any of the following: creatinine clearance of 30-50 mL/min, body weight <60 kg, concomitant us of verapamil or quinidine or dronedarone."
4,285 citations
01 Jan 2017
3,603 citations